Search Results for "Pain"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Pain. Results 221 to 230 of 274 total matches.
Treatment of Clostridioides difficile Infection
The Medical Letter on Drugs and Therapeutics • Sep 06, 2021 (Issue 1632)
, abdominal pain, and hypokalemia.
Fidaxomicin is also poorly absorbed. It can cause
nausea, vomiting ...
Clostridioides (formerly Clostridium) difficile infection
(CDI) is the most common infectious cause of
healthcare-associated diarrhea in adults. Guidelines
on management of CDI have recently been updated.
Drugs for Rheumatoid Arthritis
The Medical Letter on Drugs and Therapeutics • Nov 15, 2021 (Issue 1637)
and epigastric pain. Hemolysis may occur in
patients with glucose-6-phosphate dehydrogenase
(G6PD) deficiency ...
Rheumatoid arthritis (RA) is prevalent in 0.5% of
adults in the US; it is about 2.5 times more common
in women than in men. Guidelines for treatment
of RA from the American College of Rheumatology
were recently updated. The goal of treatment is to
minimize disease activity and prevent irreversible
joint damage.
Drugs for Inflammatory Bowel Disease
The Medical Letter on Drugs and Therapeutics • Jul 10, 2023 (Issue 1680)
, vomiting, diarrhea, headache,
and abdominal pain. Pancreatitis, hepatotoxicity,
pericarditis, pneumonitis ...
Ulcerative colitis (UC) and Crohn's disease (CD),
referred to collectively as inflammatory bowel disease
(IBD), are chronic immune-mediated inflammatory
conditions. Guidelines for treatment of UC and CD
have been updated in recent years
Med Lett Drugs Ther. 2023 Jul 10;65(1680):105-12 doi:10.58347/tml.2023.1680a | Show Introduction Hide Introduction
Drugs for Opioid Use Disorder
The Medical Letter on Drugs and Therapeutics • Sep 04, 2023 (Issue 1684)
It should not be used in patients
taking an opioid for treatment of pain. Oral naltrexone
should ...
Opioid use disorder is a chronic, relapsing disease with
physical and psychiatric components. It is associated
with economic hardship, social isolation, incarceration,
increased rates of blood-borne infections such as HIV
and viral hepatitis, adverse pregnancy outcomes, and
increased mortality. According to the NIH, there were
80,411 deaths involving an opioid in the US in 2021,
more than in any previous year. Several guidelines on
the management of opioid use disorder are available;
all recommend maintenance pharmacotherapy as the
standard of care.
Med Lett Drugs Ther. 2023 Sep 4;65(1684):137-44 doi:10.58347/tml.2023.1684a | Show Introduction Hide Introduction
Drugs for Plaque Psoriasis
The Medical Letter on Drugs and Therapeutics • Sep 30, 2024 (Issue 1712)
pain, nausea, myalgia, injection-site
reactions, influenza, neutropenia, and tinea infections ...
Mild to moderate plaque psoriasis can be treated
with topical drugs and phototherapy. Patients
with moderate to severe disease generally require
systemic therapy. Guidelines for the treatment of
psoriasis with topical therapy, phototherapy, and
systemic drugs have recently been published.
Med Lett Drugs Ther. 2024 Sep 30;66(1712):153-60 doi:10.58347/tml.2024.1712a | Show Introduction Hide Introduction
Cetirizine Ophthalmic Solution (Zerviate) for Allergic Conjunctivitis
The Medical Letter on Drugs and Therapeutics • Jun 01, 2020 (Issue 1599)
common, which
occurred in 1-7% of patients, were ocular hyperemia,
instillation-site pain ...
A 0.24% ophthalmic solution of the second-generation
H1-antihistamine cetirizine (Zerviate – Eyevance) is now
available by prescription for treatment of ocular itching
associated with allergic conjunctivitis in patients ≥2
years old. Oral cetirizine (Zyrtec, and others), which is
used for treatment of allergic conjunctivitis and rhinitis,
has been available over the counter (OTC) for years.
Ofatumumab (Kesimpta) for Multiple Sclerosis
The Medical Letter on Drugs and Therapeutics • Dec 28, 2020 (Issue 1614)
reactions, headache, urinary tract infection, back
pain, and decreased blood immunoglobulin M levels ...
The FDA has approved a subcutaneous formulation
of the recombinant human anti-CD20 antibody
ofatumumab (Kesimpta – Novartis) for treatment
of adults with relapsing forms of multiple sclerosis
(MS), including clinically isolated syndrome (initial
neurological episode), relapsing-remitting disease,
and active secondary progressive MS (SPMS).
Kesimpta is the second anti-CD20 antibody to be
approved for these indications; IV ocrelizumab
(Ocrevus), which is also approved for treatment
of primary progressive MS, was the first. An IV
formulation of ofatumumab (Arzerra) has...
Inhaled Mannitol (Bronchitol) for Cystic Fibrosis
The Medical Letter on Drugs and Therapeutics • May 31, 2021 (Issue 1625)
, hemoptysis, and
oropharyngeal pain occurred in 15.0%, 10.4%, and 7.0%,
respectively, of adults treated ...
The FDA has approved mannitol powder for oral
inhalation (Bronchitol – Chiesi) as add-on maintenance
treatment to improve pulmonary function in adults with
cystic fibrosis (CF). This product has been available in
Europe for the same indication since 2012. Another
formulation of mannitol inhalation powder (Aridol)
is approved in the US for assessment of bronchial
hyperresponsiveness.
Myfembree for Fibroid-Associated Heavy Menstrual Bleeding
The Medical Letter on Drugs and Therapeutics • Aug 09, 2021 (Issue 1630)
treated with the combination had significant decreases
in pain, distress from bleeding and pelvic ...
Myfembree (Myovant/Pfizer), an oral fixed-dose
combination of the gonadotropin-releasing hormone
(GnRH) receptor antagonist relugolix, the estrogen
estradiol, and the progestin norethindrone acetate,
has been approved by the FDA for management of
heavy menstrual bleeding associated with uterine
leiomyomas (fibroids) in premenopausal women. It is
the second product to be approved in the US for this
indication; Oriahnn, which contains the GnRH receptor
antagonist elagolix in combination with estradiol and
norethindrone acetate, was approved earlier. Relugolix
was approved for...
Azstarys (Serdexmethylphenidate/Dexmethylphenidate) for ADHD
The Medical Letter on Drugs and Therapeutics • Oct 04, 2021 (Issue 1634)
dyspepsia, dry mouth, abdominal pain, anxiety,
nervousness, restlessness, agitation, irritability, tics ...
The FDA has approved a long-acting fixed-dose
combination of the stimulant dexmethylphenidate
and the prodrug serdexmethylphenidate (Azstarys –
Corium) for once-daily treatment of attention-deficit/hyperactivity disorder (ADHD) in patients ≥6 years
old. Azstarys is the first product containing serdexmethylphenidate
to become available in the US.